Clinical Trial Update: Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial in breast cancer, including triple-negative cases, evaluated carboplatin/paclitaxel followed by doxorubicin/cyclophosphamide. The st…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Doxorubicin (doxorubicin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2023-02-01